Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Updates from IMbrave 150 in HCC

Daneng Li • 3 Jul 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Liver Cancer Antibodies Atezolizumab Bevacizumab Sorafenib
IMbrave150

Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150 (NCT03434379), a study investigating atezolizumab and bevacizumab vs sorafenib for unresectable hepatocellular carcinoma (HCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Daneng Li

3:09
Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults
Daneng Li • 4 Jul 2020
3:56
Novel developments in HCC treatment
Daneng Li • 6 Jul 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals